OffTalk - Managing Parkinson's Disease OFF Periods managingoff

Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Peter LeWitt, Professor of Neurology and Director of Movement Disorder Fellowship Program at Wayne State University, discusses the need for on-demand therapies for Parkinson’s disease OFF periods and the efficacy, safety, and patient selection for an as-needed treatment option.

Brought to US Healthcare professionals by Acorda Therapeutics 
Dr. Jennifer Durphy, Movement Disorders Specialist and Associate Professor of Neurology at Albany Medical Center, discusses treatment for the return of symptoms in Parkinson’s disease. 
Ahlskog JE et al. Mov Disord. 2001;16(3):448-458., Brown RG et al. J Psychosom Res. 2015;78(2):143-148., Chou KL et al. Parkinsonism Relat Disord. 2018;51:9-16., Hechtner MC et al. Parkinsonism Relat Disord. 2014;20(9):969-974. Stacy M et al. Mov Disord. 2005;20(6):726-733., Stocchi F. et al. Parkinsonism Relat Disord. 2014;20(2):204-211., Vijiaratnam N, Foltynie T. Drugs. 2020;80: 775-796 

Brought to US Healthcare professionals by Acorda Therapeutics 
Dr. Ray Dorsey, the David M. Levy Professor of Neurology and Director of the Center for Health + Technology at the University of Rochester Medical Center, discusses the use of telemedicine in managing Parkinson’s disease. Dr. Dorsey discusses his own approach to telemedicine, the advantages and disadvantages of telemedicine in a neurology clinic, and the utility of telemedicine post COVID-19. 
REFERENCES: Dorsey ER, et al. J Parkinsons Dis. 2020; 10(3):893-897., Parkinson J. 1817. J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):223-36., U.S. Census Bureau Quickfacts. https://www.census.gov/quickfacts/fact/table/US/PST045219. Accessed March 22, 2021., Verma S. “Early Impact Of CMS Expansion Of Medicare Telehealth During COVID-19: Health Affairs Blog.” Health Affairs, 15 July 2020, www.healthaffairs.org/do/10.1377/hblog20200715.454789/full/., Willis AW, et al. Neurology. 2011 Aug 30; 77(9), 851-7. 

Brought to US Healthcare professionals by Acorda Therapeutics 
Dr. Rajeev Kumar, Medical Director of the Rocky Mountain Movement Disorders Center, discusses the efficacy, safety, and patient selection for an as-needed treatment option for the return of Parkinson’s disease symptoms. 

Brought to US Healthcare professionals by Acorda Therapeutics 
Dr. Ron Pfeiffer, Professor, Department of Neurology, Oregon Health & Science University, discusses gastrointestinal complications in patients with Parkinson’s disease.  
 
Brudek T, et al. J Parkinsons Dis. 2019;9(s2):S331-S344., Camci G, et al. J clin neurol. 2016;12(2):147-150., Chaing HL, et al. J Mov Disord. 2019;12(2):67-83., Chandra R, et al. JCI Insight. 2017;2(12)., Chou KL, et al. Parkinsonism Relat Disord. 2018;51:9-16., Deleu D, et al. Clin Pharmacokinet. 2002;41(4):261-309., Dutta SK, et al. J Neurogastroenterol Motil. 2019;25(3):363-376., Fasano A, et al. Lancet Neurol. 2015;14(6):625-639., Goetze O, et al. Neurogastroenterol Motil. 2006;18(5):369-375., Keshavarzian A, et al. Prog Brain Res. 2020;252:357-450., Killinger B, et al. J Parkinsons Dis 2019; 9(Suppl 2): S345–S358., Liddle RA, et al. Brain Res. 2018;1693(Pt B):201-206., Maini Rekdal V, et al. Science. 2019;364(6445)., Marsden CD, et al. Lancet. 1976;1(7954):292-296., McGee DJ, et al. J Parkinsons Dis. 2018;8(3):367-374., Miraglia F, et al. Cells. 2019;8(3)., Nyholm D, et al. Opin Drug Metab Toxicol. 2008;4(2):193-203., Pfeiffer RF, et al. Parkinsonism Relat Disord. 2020;S1353-8020(20)30110-3., Pfeiffer RF, et al. Curr Treat Options Neurol. 2018;20(12):54., Rietdijk CD, et al. Front Neurol. 2017;8(37)., Safirstein BE, et al. Clin Ther. 2020;42(6):1034-1046., Svensson E, et al. Mov Disord. 2016;31(12):1918-1922., Unger MM, et al. Parkinsonism Relat Disord. 2016;32:66-72.  

Brought to US Healthcare professionals by Acorda Therapeutics 
Dr. Salima Brillman, Director of the Parkinson’s Disease and Movement Disorders Center of Silicon Valley, discusses the under treatment of OFF episodes in patients with Parkinson’s disease. 
 
Ahlskog JE, et al. Mov Disord. 2001;16(3):448-458., Armstrong MJ, et al. PLoS One. 2019;14(4):e0215384., Chou KL, et al. Parkinsonism Relat Disord. 2018;51:9-16., Connolly BS, et al. JAMA. 2014;311(16):1670-1683., Levit A, et al. Res Rev Parkinsonism. 2019;9:3-8., Olanow CW, et al. Neurology. 2009;72(21 Suppl 4):S1-136., Pahwa R, et al. Curr Med Res Opin. 2009;25(4):841-849., Rastgardani T, et al. Front. Neurol. 2019;10:892., Rastgardani T, et al. Mov Disord Clin Pract. 2018;5(5):461-470., Stacy M, et al. Mov Disord. 2005;20(6):726-733., Suarez-Cedeno G, et al. Parkinsons Dis. 2017;2017:9358153.